tiprankstipranks
Xenetic Biosciences Announces Executive Leadership Restructuring
Company Announcements

Xenetic Biosciences Announces Executive Leadership Restructuring

Pick the best stocks and maximize your portfolio:

An announcement from Xenetic Biosciences (XBIO) is now available.

Xenetic Biosciences, Inc. has elevated their CFO, James F. Parslow, to Interim CEO, revising his employment agreement to include a raised salary, a retention bonus, and a new stock option grant. Concurrently, the company has entered into separation agreements with former executives, providing them with severance and, in the case of the former CEO, immediate vesting of stock options. These corporate changes reflect Xenetic’s strategic adjustments within its leadership structure.

For detailed information about XBIO stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyXenetic extends research collaboration with University of Virginia
TheFlyXenetic enters clinical trial services agreement with PeriNess
TheFlyXenetic presents preclinical data on DNase I with CAR T cells in murine model
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App